Lymphoma

In June 2019, the FDA approved a new type of immunotherapy called Polivy, for use in combination with other drugs, in patients with previously treated diffuse large B-cell lymphoma (DLBCL), offering new options for patients whose cancer has returned.

Brigid Wallace contemplates the choices she made when living in the “new normal” after her cancer diagnosis. She describes the struggles and personal victories that tested her faith and strength after she learned she had non-Hodgkin lymphoma.

In February 2019, the FDA issued a letter to raise awareness of the risk for a rare type of lymphoma, BIA-ALCL, that is linked to all types of breast implants. Although this is an uncommon reaction to implants, all women who have or intend to get an implant after breast cancer should be aware of this risk. Learn more about this risk here.

Many patients with mantle-cell lymphoma face challenges related to the cost of their medications and other expenses associated with their care. Fortunately, assistance is available for many patients in need.

Many clinical trials are taking place to investigate new drugs for treating mantle-cell lymphoma. Patients who are thinking about participating in a clinical trial should speak with their healthcare team to get all the facts before making their decision.

Cancer treatment can be expensive, with numerous unplanned expenses. Fortunately, members of the healthcare team can help guide patients to the resources they need to plan ahead.

Although stem-cell transplantation can be an effective treatment for mantle-cell lymphoma, patients have many things to consider when deciding whether this option is appropriate for them.

It is an exciting time for mantle-cell lymphoma research, with several new therapeutic options showing promise in treating this rare but often aggressive form of non-Hodgkin lymphoma.